News
SHPH
3.900
+2.01%
0.077
Shuttle Pharmaceuticals Holdings, Inc. Amends Securities Purchase Agreement and Issues Milestone Pre-Funded Warrants
NASDAQ · 9h ago
Shuttle Pharmaceuticals Issues Pre-Funded Warrants Following Milestone Events
TipRanks · 13h ago
Shuttle Pharmaceuticals Reports Delay in Quarterly Filing
TipRanks · 2d ago
Weekly Report: what happened at SHPH last week (1109-1113)?
Weekly Report · 4d ago
Weekly Report: what happened at SHPH last week (1102-1106)?
Weekly Report · 11/09 09:49
Shuttle Pharmaceuticals Holdings, Inc. Engages Bush & Associates CPA LLC on November 2, 2026
NASDAQ · 11/07 03:09
Weekly Report: what happened at SHPH last week (1026-1030)?
Weekly Report · 11/02 09:49
Weekly Report: what happened at SHPH last week (1019-1023)?
Weekly Report · 10/26 09:49
Shuttle Pharmaceuticals Holdings, Inc. Dismisses Forvis Mazars, LLP
NASDAQ · 10/23 01:08
Weekly Report: what happened at SHPH last week (1012-1016)?
Weekly Report · 10/19 09:49
Weekly Report: what happened at SHPH last week (1005-1009)?
Weekly Report · 10/12 09:52
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 10/08 17:05
Weekly Report: what happened at SHPH last week (0928-1002)?
Weekly Report · 10/05 09:52
Weekly Report: what happened at SHPH last week (0921-0925)?
Weekly Report · 09/28 09:49
Shuttle Pharmaceuticals Q2 EPS $(3.10) Up From $(32.90) YoY
Benzinga · 09/24 22:02
Weekly Report: what happened at SHPH last week (0914-0918)?
Weekly Report · 09/21 09:49
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 09/17 12:05
Shuttle Pharmaceuticals Restructures Capital Through New Securities
TipRanks · 09/16 10:46
Weekly Report: what happened at SHPH last week (0907-0911)?
Weekly Report · 09/14 09:52
Shuttle Pharmaceuticals Shareholders Approve Merger and Renaming
TipRanks · 09/11 11:57
More
Webull provides a variety of real-time SHPH stock news. You can receive the latest news about Shuttle Pharmaceuticals Holdings, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SHPH
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.